CLAIMS

1. Use of a therapeutic agent in the manufacture of a medicament for the treatment of nerve damage symptoms in a patient,

the therapeutic agent being a formulation comprising mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells,

wherein the therapeutic agent is to be intravenously administered to the patient; and wherein the therapeutic agent is to be administered to the patient in combination with the stimulation of a nerve of the patient; and

wherein the stimulation is selected from at least one of the following : motor stimulation, sensory stimulation, electrical stimulation, magnetic stimulation, stimulation of language-related brain areas by language-mediated communication, and higher brain function stimulation by memory training, attention training, executive function training and social behavior training; and

wherein the stimulation is to be performed during the intravenous administration to 6 hours after the intravenous administration.

2. The use of claim 1,

wherein the stimulation is to be applied to at least one area selected from the group consisting of : an area of nerve damage, an area surrounding the periphery of an area of nerve

damage, an area adjacent to an area of nerve damage, and an area capable of compensating for a function of an area of nerve damage.